Bioharvest Sciences, Inc. ( (BHST) ) has released its Q1 earnings. Here is a breakdown of the information Bioharvest Sciences, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences Inc., a company specializing in Botanical Synthesis technology, operates in the health and wellness sector, developing plant-based molecules without growing the underlying plants. It serves as both a contract development and manufacturing organization and a creator of proprietary nutraceutical products.
In its first quarter of 2025, BioHarvest Sciences reported a significant revenue increase of 47% year-over-year, reaching $7.9 million, surpassing management’s guidance. The company also achieved a notable expansion in gross margins, reflecting its strategic growth in the VINIA® product line and CDMO business.
Key highlights from the earnings report include the growth of VINIA® subscribers to over 50,000 and the successful completion of Stage 1 development for a CDMO contract with a pharmaceutical company. The company also reported advancements in its proprietary olive cell compound, which shows potential in reducing fat accumulation in human liver cells.
Despite a net loss of $2.3 million, BioHarvest’s financial performance showed improvement compared to the previous year, with a substantial reduction in net loss from $6.6 million. The company’s strategic focus on expanding its product lines and increasing its CDMO partnerships is expected to drive further growth.
Looking ahead, BioHarvest Sciences anticipates continued growth in its products and services, leveraging its Botanical Synthesis platform to meet the rising demand for health and wellness solutions. The company is poised for further expansion and increased shareholder value through its diversified business model.